减肥药巨头中场战事,国产GLP-1“围剿”司美

动脉网
Sep 15

减肥药巨头竞争激烈,诺和诺德新CEO杜麦克履新后,将第一把火烧向内部组织架构,宣布全球大规模重组并裁员约9000人,旨在精简架构、提高决策速度,并将资源重新配置,以促进公司在糖尿病和肥胖症领域的增长。此举是GLP-1领域竞争加剧的结果,诺和诺德与礼来制药交锋已进入“全方位对抗”阶段,新药临床疗效比拼是核心焦点。9月诺和诺德公布司美格鲁肽与礼来替尔泊肽“头对头”研究数据,显示司美格鲁肽在减重及降低...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10